SOTAC2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member SOTAC2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SOTAC 2023-04-01 2024-03-31 INR Yearly true Cash Flow Indirect Audited Consolidated 521892000.00 4251000.00 526143000.00 402148000.00 16932000.00 -9448000.00 19380000.00 7957000.00 17151000.00 51948000.00 506068000.00 20075000.00 -2338000.00 17737000.00 0.00 17737000.00 11159000.00 -17253000.00 -6094000.00 23831000.00 0.00 0.00 0.00 23831000.00 0.00 -1643000.00 25474000.00 110500000.00 10 2.80 2.80 0.00 0.00 0.00 [1] The consolidated audited financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable [2] The above consolidated audited financial results for the year ended March 31, '24 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on May 17, '24. [3] The figures for the half year ended 31st March, '24 are the Balancing figures between the audited figures in respect of full financial year and uaudited figures in respect of first half of the financial year 23-24. [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary. [5] Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company. [6]During the last quarter,Holding company has acquired 3,00,000 equity shares of Sotac Life Science Private Limited The Subsidiary having face value of Rs. 10/- each fully paid up for cash at the price of Rs. 10/- per equity share (share premium - NIL) aggregating to Rs.30.00/- Lakhs. [7] During the year the Company has also aquired 300000 Equity Shares of Sotac Life Science Private Limited having face value of Rs. 10/- each by off Market. [8]The Status of investor's complaints during the half year ended on 31st March,'24 as under:- Complaints pending at the beginning of the period Nill Complaints received during the period Nill Complaints disposed during the period Nill Complaints resolved at the end of the period Nill [9] List of the Entities Consolidated in the Statement: Name of the Subsidaries Companies Relationship % of Holding as on 31st March, 24 Voting Power Sotac Healthcare Private Limited Subsidary 71.00% Directly Sotac Research Private Limited Subsidary 100.00% Directly Sotac Lifesciences Private Limited Subsidary 54.27% Directly Audited Consolidated 1038305000.00 4862000.00 1043167000.00 777569000.00 26158000.00 -7610000.00 39957000.00 17034000.00 31005000.00 117077000.00 1001190000.00 41977000.00 -2338000.00 39639000.00 0.00 39639000.00 20885000.00 -17039000.00 3846000.00 35793000.00 0.00 0.00 0.00 357.93 0.00 -7020000.00 42813000.00 110500000.00 10 342092000.00 3.90 3.90 0.00 0.00 0.00 other expense 51948000.00 other expense 117077000.00 17034000.00 31005000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48039000.00 -43676000.00 -115472000.00 -38558000.00 35003000.00 -27563000.00 -12833000.00 -203098000.00 -155059000.00 -115420000.00 -50000.00 0.00 -467000.00 20885000.00 -24396000.00 -161218000.00 0.00 0.00 -161218000.00 0.00 0.00 1287000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 91000.00 148014000.00 0.00 163000.00 0.00 0.00 50000.00 467000.00 0.00 -50837000.00 0.00 -196793000.00 0.00 0.00 -196793000.00 238295000.00 0.00 0.00 43622000.00 15422000.00 17034000.00 0.00 0.00 45912000.00 295373000.00 0.00 0.00 295373000.00 -62638000.00 0.00 -62638000.00 96816000.00 34178000.00